BI 764198 for COVID-19: real-time analysis

Download Image

Post

c19early.org

BI 764198 for COVID-19

1 study with 129 patients

Serious outcome risk

BI 764198

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 BI 764198 studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−117%

Mortality (1)−117%

RCTs (1)−117%

Late (1)−117%

00.511.5+

← BI 764198
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

BI 764198 is an oral, small molecule inhibitor of the transient receptor potential channel 6 (TRPC6), investigated for the potential to reduce COVID-19-related lung injury and progression to ARDS.


Apr 6 2023	Ware et al., Thorax, doi:10.1136/thorax-2022-219668	TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial
Apr 6 2023	117% higher mortality (p=0.18), 12% higher progression (p=0.84), and 42% worse recovery (p=0.48). RCT 129 hospitalized COVID-19 patients requiring non-invasive oxygen support showing no benefit and potential harm with BI 764198 (TRPC6 inhibitor). The study was terminated early due to lack of efficacy and an imbalance of fatal events (..